0000000000600306

AUTHOR

Jacques Jolivet

showing 1 related works from this author

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory …

2011

Background XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9 that is overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy. Methods Twenty-seven patients with AML who were refractory to initial induction chemotherapy were randomized and treated with AEG35156 (650 mg) in combination with high-dose cytarabine and idarubicin. Thirteen patients were randomized and treated with high-dose cytarabine and idarubic…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOligonucleotidesMedizinPhases of clinical researchX-Linked Inhibitor of Apoptosis ProteinPharmacologyYoung AdultInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIdarubicinAgedAged 80 and overChemotherapybusiness.industryRemission InductionInduction chemotherapyMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseXIAPLeukemia Myeloid AcuteLeukemiaTreatment OutcomeOncologyCytarabineFemalebusinessmedicine.drug
researchProduct